文献速递肾移植

晚期转换为贝拉西普的肾移植受者采用无激素方案疗效相似

Similar Efficacy in Belatacept-Converted Kidney Transplant Recipients With Steroid-Avoiding Regimen.
PubMed 文献 · Kidney Int Rep · 2024-12-20

这项回顾性多中心研究纳入512例肾移植至少6个月后转换为贝拉西普的受者,比较无激素(BelaS-,199例)与联合激素(BelaS+,313例)方案。结果显示两组急性排斥率和移植物存活相似,但BelaS+组患者死亡率、严重感染及新发DSA更高,提示在低致敏患者中无激素方案安全有效。

要点

  • 晚期转换为贝拉西普时避免激素,急性排斥率和移植物存活与联合激素方案相似。
  • 无激素组患者死亡率和严重感染发生率显著低于联合激素组。
  • 联合激素组新发DSA比例更高,但转换后DSA发生率总体稳定。

核心结论

  • 在晚期转换为贝拉西普的肾移植受者中,无激素方案与联合激素方案疗效相似,且死亡率和严重感染更低,尤其适用于低致敏患者。

研究设计与样本

  • 回顾性多中心研究,纳入4家法国移植中心512例肾移植至少6个月后转换为贝拉西普的受者,其中199例无激素(BelaS-),313例联合激素(BelaS+)。

主要发现

  • BelaS-组与BelaS+组急性排斥率分别为6.0%和6.1%(P=0.126),移植物丢失率分别为4.5%和7.3%(P=0.198)。
  • BelaS+组患者死亡率16.6%,显著高于BelaS-组的3%(P<0.001)。
  • BelaS+组严重感染累积发生率为13.7 vs 6.7事件/100人年,CMV病、诺如病毒感染和COVID-19住院率均更高(P<0.001)。
  • BelaS+组转换时致敏比例更高(DSA 21.8% vs 6.6%,P<0.001),新发DSA更多(4.9% vs 1.0%,P<0.001)。
  • 激素使用(P=0.009)、转换时年龄(P=0.0001)、糖尿病(P=0.001)及贝拉西普相关严重感染(P=0.0005)为死亡独立危险因素。

临床怎么用

  • 对于晚期转换为贝拉西普的低致敏肾移植受者,可考虑采用无激素方案以减少死亡和严重感染风险。

局限性

  • 回顾性研究设计,BelaS+组转换时致敏比例更高,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Belatacept offers a valuable alternative to calcineurin inhibitors (CNIs) for reducing toxicity in kidney transplant recipients (KTRs). No study has evaluated the efficacy and safety of late-conversion belatacept with steroid avoidance in KTRs. METHODS: This retrospective multicentric study evaluated the efficacy and safety of a belatacept-based steroid-avoiding therapy, in comparison with concomitant steroid use. The study included KTRs from 4-French transplant centers who were converted to belatacept at least 6 months posttransplantation. RESULTS: Overall, 512 KTRs were converted to belatacept in a median time of 38 (15.7-83.2) months after kidney transplantation (KT), including 199 patients without steroids after conversion (BelaS-). Median follow-up time was 78.9 (50.3-129.4) months. Compared with the 313 KTRs who had concomitant steroid use (BelaS+), BelaS- patients had a similar acute rejection (AR) rate (19 [6.1%] and 12 [6.0%] patients, P = 0.126, including 13 [68.4%] and 5 [41.7%] T cell-mediated rejection in BelaS+ and BelaS- patients, respectively), and a similar graft survival (graft loss occurred in respectively 23 [7.3%] and 9 [4.5%] patients in BelaS+ and BelaS- groups [P = 0.198]). However, patient mortality was higher among BelaS+ patients (16.6% vs. 3%, P < 0.001). Steroid use was an independent risk factor of mortality (P = 0.009) along with age (P = 0.0001) and diabetes (P = 0.001) at switch and the occurrence of severe infections with belatacept use (P = 0.0005). In addition, BelaS+ patients experienced a higher incidence of severe infections (cumulative incidence of 13.7 vs. 6.7 events/100-person-year), cytomegalovirus (CMV) disease (P < 0.001), infection by norovirus (P < 0.001), and hospitalization with COVID-19 (P < 0.001). BelaS+ patients were significantly more sensitized at conversion (donor-specific antibodies [DSA] in 21.8% vs. 6.6% in BelaS- patients, P < 0.001). DSA incidence remained stable after conversion. BelaS+ patients developed significantly more de novo DSA (14 [4.9%] vs. 2 [1.0%], P < 0.001). CONCLUSION: Avoiding steroids in KTRs who are late-converted to belatacept is associated with a similar efficacy along with lower mortality and reduced incidence of severe infections in selected low-sensitized patients.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chavarot N, Cabezas L, Kaminski H, et al. Similar Efficacy in Belatacept-Converted Kidney Transplant Recipients With Steroid-Avoiding Regimen. Kidney Int Rep. 2024. PMID: 40225396. doi:10.1016/j.ekir.2024.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。